- Home
- BLAC vs ICCC Comparison
BLAC vs ICCC Comparison
Compare BLAC & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLAC
- ICCC
- Stock Information
- Founded
- BLAC 2020
- ICCC 1982
- Country
- BLAC United States
- ICCC United States
- Employees
- BLAC N/A
- ICCC N/A
- Industry
- BLAC
- ICCC Biotechnology: Pharmaceutical Preparations
- Sector
- BLAC
- ICCC Health Care
- Exchange
- BLAC NYSE
- ICCC Nasdaq
- Market Cap
- BLAC 46.9M
- ICCC 45.9M
- IPO Year
- BLAC 2023
- ICCC 1987
- Fundamental
- Price
- BLAC $11.66
- ICCC $5.11
- Analyst Decision
- BLAC
- ICCC
- Analyst Count
- BLAC 0
- ICCC 0
- Target Price
- BLAC N/A
- ICCC N/A
- AVG Volume (30 Days)
- BLAC 4.0K
- ICCC 8.9K
- Earning Date
- BLAC 01-01-0001
- ICCC 02-25-2025
- Dividend Yield
- BLAC N/A
- ICCC N/A
- EPS Growth
- BLAC N/A
- ICCC N/A
- EPS
- BLAC N/A
- ICCC N/A
- Revenue
- BLAC N/A
- ICCC $23,838,001.00
- Revenue This Year
- BLAC N/A
- ICCC N/A
- Revenue Next Year
- BLAC N/A
- ICCC N/A
- P/E Ratio
- BLAC N/A
- ICCC N/A
- Revenue Growth
- BLAC N/A
- ICCC 46.37
- 52 Week Low
- BLAC $10.56
- ICCC $3.34
- 52 Week High
- BLAC $13.40
- ICCC $5.82
- Technical
- Relative Strength Index (RSI)
- BLAC 57.71
- ICCC 51.53
- Support Level
- BLAC $11.22
- ICCC $4.86
- Resistance Level
- BLAC $12.54
- ICCC $5.50
- Average True Range (ATR)
- BLAC 0.24
- ICCC 0.34
- MACD
- BLAC 0.02
- ICCC -0.04
- Stochastic Oscillator
- BLAC 33.33
- ICCC 39.06
About BLAC BELLEVUE LIFE SCIENCES ACQ CORP
Bellevue Life Sciences Acquisition Corp is a blank check company.
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.